{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:37:00Z","timestamp":1774049820968,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.antiviral.2020.104829","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T09:15:24Z","timestamp":1592644524000},"page":"104829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir"],"prefix":"10.1016","volume":"180","author":[{"given":"Kimiyasu","family":"Shiraki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Daikoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104829_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj1520023","article-title":"The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates","volume":"152","author":"Beis","year":"1975","journal-title":"Biochem. J."},{"key":"10.1016\/j.antiviral.2020.104829_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1128\/AAC.18.3.443","article-title":"In vitro susceptibility of varicella-zoster virus to acyclovir","volume":"18","author":"Biron","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1086\/514011","article-title":"Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group","volume":"176","author":"Bodsworth","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104829_bib4","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat. Med."},{"issue":"Pt 6","key":"10.1016\/j.antiviral.2020.104829_bib6","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1099\/0022-1317-72-6-1441","article-title":"Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells","volume":"72","author":"Daikoku","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104829_bib7","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1749-6632.2011.06358.x","article-title":"Evolution of sexually transmitted and sexually transmissible human herpesviruses","volume":"1230","author":"Davison","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Pt 9","key":"10.1016\/j.antiviral.2020.104829_bib8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1099\/0022-1317-67-9-1759","article-title":"The complete DNA sequence of varicella-zoster virus","volume":"67","author":"Davison","year":"1986","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104829_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am. J. Med."},{"issue":"Suppl. B","key":"10.1016\/j.antiviral.2020.104829_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/12.suppl_B.9","article-title":"The biochemistry and mechanism of action of acyclovir","volume":"12","author":"Elion","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1128\/AAC.42.5.1139","volume":"42","author":"Gnann","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib12","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/JCM.39.12.4362-4369.2001","article-title":"Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR","volume":"39","author":"Griscelli","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104829_bib13","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/vir.0.18880-0","article-title":"Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir","volume":"84","author":"Harris","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104829_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0166-3542(95)00007-9","article-title":"Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV","volume":"27","author":"Hasegawa","year":"1995","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0166-3542(98)00057-6","article-title":"Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants","volume":"40","author":"Ida","year":"1999","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib16","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1099\/0022-1317-82-11-2761","article-title":"Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir","volume":"82","author":"Kamiyama","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104829_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2018.10.024","article-title":"Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection","volume":"158","author":"Katsumata","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104829_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1348-0421.1993.tb01719.x","article-title":"Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus","volume":"37","author":"Kawai","year":"1993","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2020.104829_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.antiviral.2020.104829_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2020.104829_bib21","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s12325-017-0642-4","article-title":"Pharmacokinetics and safety of amenamevir in healthy subjects: analysis of four randomized phase 1 studies","volume":"34","author":"Kusawake","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.antiviral.2020.104829_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0166-3542(84)90013-5","article-title":"In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds","volume":"4","author":"Machida","year":"1984","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1128\/AAC.20.1.47","article-title":"Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils","volume":"20","author":"Machida","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib24","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1128\/JVI.02137-08","article-title":"The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level","volume":"83","author":"Reichelt","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104829_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-115-1-19","article-title":"Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection","volume":"115","author":"Safrin","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2020.104829_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.07.010","article-title":"Inhibitory activity of oxyresveratrol on wild-type and drug-resistant varicella-zoster virus replication in vitro","volume":"84","author":"Sasivimolphan","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib27","doi-asserted-by":"crossref","first-page":"16201","DOI":"10.1038\/nmicrobiol.2016.201","article-title":"Targeting the ATP-dependent formation of herpesvirus ribonucleoprotein particle assembly as an antiviral approach","volume":"2","author":"Schumann","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104829_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2007.08.009","article-title":"Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and\/or the DNA polymerase genes.","volume":"77","author":"Sergerie","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1358\/dot.2017.53.11.2724803","article-title":"Helicase-primase inhibitor amenamevir for herpesvirus infection: towards practical application for treating herpes zoster","volume":"53","author":"Shiraki","year":"2017","journal-title":"Drugs Today"},{"key":"10.1016\/j.antiviral.2020.104829_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0166-3542(92)90039-8","article-title":"Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus","volume":"18","author":"Shiraki","year":"1992","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/infdis\/150.2.306","article-title":"Susceptibility to acyclovir of Oka-strain varicella vaccine and vaccine-derived viruses isolated from immunocompromised patients","volume":"150","author":"Shiraki","year":"1984","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104829_bib31","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1086\/379835","article-title":"Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts","volume":"188","author":"Shiraki","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104829_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1128\/AAC.32.10.1547","article-title":"Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2","volume":"32","author":"Suzutani","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/09563202930040S601","article-title":"The mode of action of penciclovir","volume":"4","author":"Vere Hodge","year":"1993","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2020.104829_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers","volume":"54","author":"Weller","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2020.104829_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2016.12.008","article-title":"Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor","volume":"139","author":"Yajima","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104829_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1128\/iai.28.2.536-541.1980","article-title":"Virus replication and localization of varicella-zoster virus antigens in human embryonic fibroblast cells infected with cell-free virus","volume":"28","author":"Yamanishi","year":"1980","journal-title":"Infect. Immun."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:29Z","timestamp":1759062809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":37,"alternative-id":["S0166354220302436"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104829","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104829"}}